From: Fierce Pharma By: Eric Sagonowsky Lilly Launches Real-World Study to Benchmark Emgality Against Migraine Rivals Eli Lilly’s CGRP migraine prevention med Emgality trailed its rivals onto the market, but it’s been a force in the dogfight for market share. Now, in an effort to learn more about how physicians choose between the med and its competitors, the company has started a real-world evidence study...(read more).
From: FiercePharma By: Kyle Blankenship Pro-AbbVie Bias May be Driving Rheumatologist Confidence in Newcomer Rinvoq: Analyst Between AbbVie's two newly approved blockbusters-in-waiting, psoriasis med Skyrizi's booming sales have drawn some analysts' eyes away from highly-touted rheumatoid arthritis drug Rinvoq. But among physicians, Rinvoq is becoming a darling, one analyst says––and an "AbbVie halo" could be major part of that...(read more).
From: Multiple Sclerosis News Today By: Ana Pena, PHD Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says Genentech‘s Ocrevus (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosis (SPMS) among U.S. neurologists, even though Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) were approved in March to treat this same MS group, according to a 2019 report by Spherix Global Insights...(read more).
From: Multiple Sclerosis News Today By: Ana Pena, PHD Mavenclad, Ocrevus Use Rising in EU as Injectables and Tysabri Decline, Spherix Reports Prescriptions of two multiple sclerosis (MS) treatments — Merck KGaA‘s Mavenclad (cladribine) and Roche‘s Ocrevus (ocrelizumab) — have been rising in Europe over the past six months, bolstered by greater market access and compassionate use programs, according to a survey of 250 EU neurologists run by Spherix Global Insights...(read more).
From: TheStreet By: Tony Owusu Biogen shares were falling in trading Friday after analysts at Piper Jaffray downgraded the stock to neutral from overweight on concerns about competitive pressures for the suite of the company's multiple sclerosis treatments. The firm also lowered its price target to $250 from $280 per share. Shares fell in trading by 1.4% to $236.36. Piper Jaffray analyst Christopher Raymond cited new neurologist survey data from Spherix Global Insights that "spells bad news for both Tecfidera and Tysabri in the near and long term." The company's Tecfidera multiple sclerosis [...]